Biocon Ltd

Biocon Ltd is up for a third straight session today. The stock is quoting at Rs 383.95, up 1.31% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 25755.6. The Sensex is at 83702.57, up 0.38%. Biocon Ltd has slipped around 0.56% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 1.33% in last one month and is currently quoting at 22505.4, down 0.86% on the day. The volume in the stock stood at 17.89 lakh shares today, compared to the daily average of 26.3 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 384.45, up 1.33% on the day. Biocon Ltd is down 2.48% in last one year as compared to a 11% jump in NIFTY and a 1.13% jump in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending September 25.Powered by Capital Market - Live

Biocon announced the successful completion of a Qualified Institutions Placement (QIP), raising Rs 4,150 crore (~USD 460 million) through the issuance of 112,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per equity share (including a premium of Rs 363.35 per equity share). The QIP, which opened on 12 January 2026, and closed on 14 January 2026, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in Biocon's growth prospects. The proceeds from the QIP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics, including repayment of debt availed in this regard. Biocon recently announced that its Board of Directors had approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon Biologics a wholly owned subsidiary of the Company.Powered by Capital Market - Live

Biocon will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live

Securities in F&O Ban: Shares of Steel Authority of India (SAIL) and Sammaan Capital are banned from F&O trading on 7 January 2026. Stocks to Watch: Biocon's subsidiary, Biocon Biologics will introduce three new oncology biosimilars at a US event. Titan Company's consumer business registered a growth of 40% YoY in Q3FY26. A total of 56 stores (net) were added during the quarter expanding Titan's combined retail network presence to 3,433 stores. Lodha Developers' pre sales jumped 25% to Rs 56,200 crore in Q3 FY26 compared with Rs 45,100 crore in Q3 FY25. Collections declined 17% YoY to Rs 35,600 crore in Q3 FY26. Jubilant Foodworks' consolidated revenue stood at Rs 2,438.7 crore in Q3 FY26, up 13.4% YoY. Domino's recorded a Like-For-Like (LFL) growth of 5%. Senco Gold reported a 51% revenue growth in Q3 FY26, driven by robust performances across its businesses. The retail business reported around 49% growth while SSSG growth stood at 39%. Godrej Consumer Products' standalone business is well positioned to deliver double-digit revenue growth for the quarter, underpinned by close to double-digit underlying volume growth (UVG), albeit on a supportive comparator. Personal Care is expected to record mid-single-digit value growth, driven by a marked recovery in the soaps category.Powered by Capital Market - Live

Biocon Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 399.7, up 0.1% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.01% on the day, quoting at 26175.65. The Sensex is at 85535.57, down 0.04%. Biocon Ltd has risen around 1.13% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has risen around 1.82% in last one month and is currently quoting at 22927.9, down 0.11% on the day. The volume in the stock stood at 12.75 lakh shares today, compared to the daily average of 34.28 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 400.5, up 0.18% on the day. Biocon Ltd is up 16.02% in last one year as compared to a 10.32% spurt in NIFTY and a 1.52% spurt in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending September 25.Powered by Capital Market - Live

According to an exchange filing, under this new agreement, Biocon Biologics will assume end-to-end responsibility for manufacturing and commercialization along with rights for any additional development activities. The new agreement supersedes the existing collaboration agreement between Biocon Biologics and FKB for biosimilar Adalimumab, under which Biocon Biologics only had commercialization rights. Under the terms of this agreement, FKB will participate in the development of the product and will offset certain development costs incurred by Biocon Biologics. In turn, Biocon Biologics will pay a technology license fee and royalties on sales to FKB for a specified tenure. Commercial production of the biosimilar Adalimumab at Biocon Biologics' facilities will commence after successful completion of technology transfer and receipt of necessary regulatory approvals. Biocon Biologics initially acquired the commercial rights to biosimilar Adalimumab in 2022 through its acquisition of Viatris' global biosimilars business. Viatris had previously in-licensed the product from FKB. Under the earlier arrangement, FKB manufactures and supplies the product to Biocon Biologics, which holds global commercial rights for HULIO. Adalimumab is one of the three immunology biosimilars in Biocon Biologics' overall portfolio, which underscores the company's strategic focus on expanding access to biologics for immune-mediated diseases worldwide. Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said, 'This agreement with FKB provides Biocon Biologics the manufacturing rights to biosimilar Adalimumab, granting us end-to-end control over the product. This strategic move enhances flexibility and cost efficiency, reinforcing our commitment to expanding affordable access to high-quality biologics for patients with inflammatory diseases globally.' Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. On a consolidated basis, Biocon reported a net profit of Rs 84.50 crore in Q2 September 2025 as against a net loss of Rs 16 crore in Q2 September 2024. Net sales rose 20.24% YoY to Rs 4262.50 crore in Q2 September 2025. The counter added 0.43% to currently trade at Rs 400.75 on the BSE. Powered by Capital Market - Live

The drug-device combination will be marketed in the Netherlands under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management. The launch follows the approval from the Medicines Evaluation Board (MEB), Netherlands, earlier this year and will mark the first country in the European Union where the Company will directly launch Liraglutide under its own brand. Siddharth Mittal, chief executive officer and managing director, Biocon, said: 'The launch of Liraglutide in the Netherlands marks a significant milestone in expanding Biocon's GLP-1 portfolio across key global markets, and reinforces the strategic importance of peptide-based therapies within our portfolio. With our vertically integrated, end-to-end capabilities, we are uniquely positioned to deliver high-quality, affordable metabolic treatments at scale. Launching Diavorin and Vobexoryn under our own brand in Europe reflects not only our scientific and manufacturing excellence, but also our long-standing commitment to broadening access to advanced therapies for diabetes and obesity. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. On a consolidated basis, Biocon reported net profit of Rs 84.50 crore in Q2 September 2025 as against net loss of Rs 16 crore in Q2 September 2024. Net sales rose 20.24% YoY to Rs 4262.50 crore in Q2 September 2025. The scrip shed 0.21% to currently trade at Rs 385.85 on the BSE. Powered by Capital Market - Live

Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes (gVictoza') and obesity (gSaxenda'), in the Netherlands through its distribution partner Pharmamedic B.V. The drug-device combination will be marketed in the Netherlands under the brand names Diavorin' for diabetes and Vobexoryn' for chronic weight management. The launch follows the approval from the Medicines Evaluation Board (MEB), Netherlands, earlier this year and will mark the first country in the European Union where the Company will directly launch Liraglutide under its own brand.Powered by Capital Market - Live

This follows an earlier settlement that addressed the U.S. and Canadian markets. The agreement clears the way for Biocon Biologics to commercialize Yesafili globally. Yesafili is a vascular endothelial growth factor (VEGF) inhibitor used to treat multiple ophthalmology conditions, including neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV). As part of the agreement, all pending litigation among Biocon Biologics, Regeneron, and Bayer has been dismissed. Biocon Biologics plans to launch Yesafili in the United Kingdom in January 2026, followed by launches in other settled countries in March 2026, or earlier in certain circumstances. The other terms of the settlement remain confidential. The European Commission (EC) and the Medicines & Healthcare products Regulatory Agency (MHRA) have previously approved YESAFILI. Yesafili has already received approval from the European Commission (EC) and the UK Medicines & Healthcare products Regulatory Agency (MHRA). Biocon Biologics had earlier secured market entry for the U.S. in April 2025, targeting the second half of calendar year 2026, and launched the product in Canada earlier this year, with market entry secured in March 2024. Shreehas Tambe, CEO & managing director, Biocon Biologics, said, 'This settlement paves the way for Biocon Biologics to make available our biosimilar Aflibercept globally. This milestone expands our presence in the ophthalmology therapeutic area as we work closely with healthcare systems to increase access to patients everywhere.' Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. On a consolidated basis, Biocon reported net profit of Rs 84.50 crore in Q2 September 2025 as against net loss of Rs 16 crore in Q2 September 2024. Net sales rose 20.24% YoY to Rs 4262.50 crore in Q2 September 2025. The counter added 1.34% to currently trade at Rs 386.65 on the BSE. Powered by Capital Market - Live

Biocon announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 31 December 2025.Powered by Capital Market - Live